KR20210013062A - 염증성 질환을 보유하는 환자의 선택 및 치료를 위한 방법 및 시스템 - Google Patents

염증성 질환을 보유하는 환자의 선택 및 치료를 위한 방법 및 시스템 Download PDF

Info

Publication number
KR20210013062A
KR20210013062A KR1020207033851A KR20207033851A KR20210013062A KR 20210013062 A KR20210013062 A KR 20210013062A KR 1020207033851 A KR1020207033851 A KR 1020207033851A KR 20207033851 A KR20207033851 A KR 20207033851A KR 20210013062 A KR20210013062 A KR 20210013062A
Authority
KR
South Korea
Prior art keywords
seq
antibody
binding fragment
antigen binding
tl1a
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207033851A
Other languages
English (en)
Korean (ko)
Inventor
제닌 빌스보러프
더못 피. 맥고베른
스테판 타르간
알카 포트다르
제프리 디. 왓킨스
신디 티. 디커슨
Original Assignee
세다르스-신나이 메디칼 센터
프로메테우스 바이오사이언시즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 세다르스-신나이 메디칼 센터, 프로메테우스 바이오사이언시즈, 인크. filed Critical 세다르스-신나이 메디칼 센터
Priority to KR1020257023772A priority Critical patent/KR20250111409A/ko
Publication of KR20210013062A publication Critical patent/KR20210013062A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Transplantation (AREA)
  • General Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
KR1020207033851A 2018-04-30 2019-04-26 염증성 질환을 보유하는 환자의 선택 및 치료를 위한 방법 및 시스템 Ceased KR20210013062A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257023772A KR20250111409A (ko) 2018-04-30 2019-04-26 염증성 질환을 보유하는 환자의 선택 및 치료를 위한 방법 및 시스템

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862664720P 2018-04-30 2018-04-30
US62/664,720 2018-04-30
US201862681557P 2018-06-06 2018-06-06
US62/681,557 2018-06-06
US201862784179P 2018-12-21 2018-12-21
US62/784,179 2018-12-21
PCT/US2019/029402 WO2019212899A1 (en) 2018-04-30 2019-04-26 Methods and systems for selection and treatment of patients with inflammatory diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257023772A Division KR20250111409A (ko) 2018-04-30 2019-04-26 염증성 질환을 보유하는 환자의 선택 및 치료를 위한 방법 및 시스템

Publications (1)

Publication Number Publication Date
KR20210013062A true KR20210013062A (ko) 2021-02-03

Family

ID=68386125

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207033851A Ceased KR20210013062A (ko) 2018-04-30 2019-04-26 염증성 질환을 보유하는 환자의 선택 및 치료를 위한 방법 및 시스템
KR1020257023772A Pending KR20250111409A (ko) 2018-04-30 2019-04-26 염증성 질환을 보유하는 환자의 선택 및 치료를 위한 방법 및 시스템

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257023772A Pending KR20250111409A (ko) 2018-04-30 2019-04-26 염증성 질환을 보유하는 환자의 선택 및 치료를 위한 방법 및 시스템

Country Status (21)

Country Link
US (2) US12305236B2 (https=)
EP (2) EP4296285A3 (https=)
JP (2) JP2021532060A (https=)
KR (2) KR20210013062A (https=)
CN (1) CN112368301B (https=)
AU (1) AU2019261933B2 (https=)
CA (1) CA3098720A1 (https=)
DK (1) DK3774897T5 (https=)
ES (1) ES2962715T3 (https=)
FI (1) FI3774897T3 (https=)
HR (1) HRP20231367T1 (https=)
HU (1) HUE063908T2 (https=)
LT (1) LT3774897T (https=)
MA (1) MA52251A (https=)
MD (1) MD3774897T2 (https=)
PL (1) PL3774897T3 (https=)
PT (1) PT3774897T (https=)
RS (1) RS64747B1 (https=)
SI (1) SI3774897T1 (https=)
TW (1) TW202003573A (https=)
WO (1) WO2019212899A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4294840A4 (en) * 2021-02-17 2025-06-11 Prometheus Biosciences, Inc. ANTI-CD30L ANTIBODIES AND USES THEREOF

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014003689A (es) 2011-09-30 2014-12-05 Teva Pharmaceuticals Australia Pty Ltd Anticuerpos contra tl1a y sus usos.
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
ES2962715T3 (es) 2018-04-30 2024-03-20 Cedars Sinai Medical Center Métodos y sistemas para selección y tratamiento de pacientes con enfermedades inflamatorias
WO2020112890A1 (en) 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Rnaset2 compositions and methods of treatment therewith
KR20210130168A (ko) * 2019-02-08 2021-10-29 세다르스-신나이 메디칼 센터 Il18r1을 표적화하는 염증성 질환의 치료를 위한 방법, 시스템 및 키트
JP2022533956A (ja) 2019-05-14 2022-07-27 プロメテウス バイオサイエンシーズ，インク． Ｔｌ１ａ患者を選択する方法、システム、およびデバイス
CA3197828A1 (en) * 2020-11-13 2022-05-19 Laurens Kruidenier Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a
EP4256086A4 (en) * 2020-12-01 2025-01-15 Cedars-Sinai Medical Center METHODS AND SYSTEMS FOR STRATIFICATION OF PATIENTS WITH INFLAMMATORY DISEASES
EP4562038A1 (en) * 2022-07-27 2025-06-04 Cephalon LLC Anti-tl1a antibody formulations
CA3262839A1 (en) * 2022-07-27 2024-02-01 Cephalon Llc ANTI-TL1A ANTIBODIES FOR THE TREATMENT OF ULCERATIVE COLITIS AND CROHN'S DISEASE
WO2024143497A1 (ja) * 2022-12-28 2024-07-04 国立大学法人京都大学 Ｃｄ１５３を標的とする医薬組成物
CN121843714A (zh) 2023-08-11 2026-04-10 派拉冈医疗公司 Tl1a结合抗体及使用方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4229447A (en) 1979-06-04 1980-10-21 American Home Products Corporation Intraoral methods of using benzodiazepines
US4476116A (en) 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
US5116817A (en) 1982-12-10 1992-05-26 Syntex (U.S.A.) Inc. LHRH preparations for intranasal administration
US4596795A (en) 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US5011692A (en) 1985-12-28 1991-04-30 Sumitomo Pharmaceuticals Company, Limited Sustained pulsewise release pharmaceutical preparation
US4755386A (en) 1986-01-22 1988-07-05 Schering Corporation Buccal formulation
US5739136A (en) 1989-10-17 1998-04-14 Ellinwood, Jr.; Everett H. Intraoral dosing method of administering medicaments
US5017381A (en) 1990-05-02 1991-05-21 Alza Corporation Multi-unit pulsatile delivery system
US5229135A (en) 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
DE69334070T2 (de) 1992-05-26 2007-01-04 Immunex Corp., Thousand Oaks Neue zytokine die cd30 binden
US5837284A (en) 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
US6391452B1 (en) 1997-07-18 2002-05-21 Bayer Corporation Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
US6652854B2 (en) 2000-08-08 2003-11-25 Immunex Corporation Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
US6960563B2 (en) 2001-08-31 2005-11-01 Morton Grove Pharmaceuticals, Inc. Spontaneous emulsions containing cyclosporine
US20060194265A1 (en) 2001-10-23 2006-08-31 Morris David W Novel therapeutic targets in cancer
US20080233119A2 (en) 2003-08-20 2008-09-25 University Of Miami Compositions and methods for treating inflammatory lung disease
WO2008106451A2 (en) * 2007-02-26 2008-09-04 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
AU2010244640A1 (en) * 2009-03-27 2011-08-11 Merck Serono S.A. Genetic severity markers in Multiple Sclerosis
US8486939B2 (en) 2009-07-07 2013-07-16 Pathway Therapeutics Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
WO2011020906A2 (en) * 2009-08-21 2011-02-24 INSERM (Institut National de la Santé et de la Recherche Médicale) sPLA2 IIA POLYMORPHISM ANALYSIS FOR THE DIAGNOSIS/PROGNOSIS OF A CARDIOVASCULAR DISEASE/EVENT
JP6124800B2 (ja) 2011-11-30 2017-05-10 中外製薬株式会社 免疫複合体を形成する細胞内への運搬体（キャリア）を含む医薬
CN117264057A (zh) * 2012-04-27 2023-12-22 诺和诺德股份有限公司 人cd30配体抗原结合蛋白
AU2013271336B2 (en) 2012-06-04 2017-11-30 Centre For Digestive Diseases Compositions and methods for treating Crohn's Disease and related conditions and infections
EP3389781B1 (en) 2015-12-15 2021-08-11 University of Miami Inhibitors of tnf superfamily costimulatory interactions and methods for uses of the same
MY191324A (en) * 2016-10-26 2022-06-15 Cedars Sinai Medical Center Neutralizing anti-tl1a monoclonal antibodies
ES2962715T3 (es) 2018-04-30 2024-03-20 Cedars Sinai Medical Center Métodos y sistemas para selección y tratamiento de pacientes con enfermedades inflamatorias

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4294840A4 (en) * 2021-02-17 2025-06-11 Prometheus Biosciences, Inc. ANTI-CD30L ANTIBODIES AND USES THEREOF

Also Published As

Publication number Publication date
EP4296285A2 (en) 2023-12-27
EP3774897A4 (en) 2022-02-16
US20210238684A1 (en) 2021-08-05
JP2024133462A (ja) 2024-10-02
CN112368301B (zh) 2025-12-02
KR20250111409A (ko) 2025-07-22
PT3774897T (pt) 2023-11-10
US12305236B2 (en) 2025-05-20
CA3098720A1 (en) 2019-11-07
CN112368301A (zh) 2021-02-12
DK3774897T3 (da) 2023-11-06
FI3774897T3 (fi) 2023-11-03
HUE063908T2 (hu) 2024-02-28
EP3774897B1 (en) 2023-09-27
MA52251A (fr) 2021-02-17
DK3774897T5 (da) 2024-08-19
AU2019261933A1 (en) 2020-12-03
EP4296285A3 (en) 2024-02-28
HRP20231367T1 (hr) 2024-02-16
LT3774897T (lt) 2023-11-10
JP7832987B2 (ja) 2026-03-18
WO2019212899A1 (en) 2019-11-07
MD3774897T2 (ro) 2024-02-29
TW202003573A (zh) 2020-01-16
ES2962715T3 (es) 2024-03-20
EP3774897A1 (en) 2021-02-17
AU2019261933B2 (en) 2025-12-18
RS64747B1 (sr) 2023-11-30
US20250290143A1 (en) 2025-09-18
JP2021532060A (ja) 2021-11-25
PL3774897T3 (pl) 2024-01-29
SI3774897T1 (sl) 2024-01-31

Similar Documents

Publication Publication Date Title
JP7832987B2 (ja) 炎症性疾患を抱える患者の選択および処置のための方法ならびにシステム
US12391752B2 (en) Methods of enriching or amplifying nucleic acids in a sample from a patient with inflammatory bowel disease
US20220290241A1 (en) Predicting extraintestinal manifestations of inflammatory bowel disease
US12540358B2 (en) RNASET2 compositions and methods of treatment therewith
US20210079473A1 (en) Methods and systems for characterizing severe crohn's disease
US20230287499A1 (en) Methods and systems for measuring post-operative disease recurrence
HK40098022A (en) Methods and systems for selection and treatment of patients with inflammatory diseases
HK40047054B (en) Methods and systems for selection and treatment of patients with inflammatory diseases
HK40047054A (en) Methods and systems for selection and treatment of patients with inflammatory diseases
EA047764B1 (ru) Способы, системы и устройства для выбора пациента в отношении tl1a
HK40066650A (zh) Tl1a患者选择方法、系统和装置
HK40043280A (en) Methods and systems for selection and treatment of patients with inflammatory diseases

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

X601 Decision of rejection after re-examination
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

A18 Application divided or continuation or continuation in part accepted

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A18-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104